| Literature DB >> 29867188 |
Lin-Lin Shen1, Noralyn B Mañucat-Tan2, Shi-Hao Gao3, Wei-Wei Li1, Fan Zeng1, Chi Zhu1, Jun Wang1, Xian-Le Bu1, Yu-Hui Liu1, Chang-Yue Gao1, Zhi-Qiang Xu1, Larisa Bobrovskaya2, Peng Lei4, Jin-Tai Yu5, Weihong Song6, Hua-Dong Zhou1, Xiu-Qing Yao7, Xin-Fu Zhou8, Yan-Jiang Wang9,10.
Abstract
Tau pathology is characterized as a form of frontotemporal lobar degeneration (FTLD) known as FTLD-tau. The underlying pathogenic mechanisms are not known and no therapeutic interventions are currently available. Here, we report that the neurotrophin receptor p75NTR plays a critical role in the pathogenesis of FTLD-tau. The expression of p75NTR and the precursor of nerve growth factor (proNGF) were increased in the brains of FTLD-tau patients and mice (P301L transgenic). ProNGF-induced tau phosphorylation via p75NTR in vitro, which was associated with the AKT/glycogen synthase kinase (GSK)3β pathway. Genetic reduction of p75NTR in P301L mice rescued the memory deficits, alleviated tau hyperphosphorylation and restored the activity of the AKT/GSK3β pathway. Treatment of the P301L mice with the soluble p75NTR extracellular domain (p75ECD-Fc), which can antagonize neurotoxic ligands of p75NTR, effectively improved memory behavior and suppressed tau pathology. This suggests that p75NTR plays a crucial role in tau paGSKthology and represents a potential druggable target for FTLD-tau and related tauopathies.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29867188 DOI: 10.1038/s41380-018-0071-z
Source DB: PubMed Journal: Mol Psychiatry ISSN: 1359-4184 Impact factor: 15.992